Literature DB >> 7847435

Increase of myocardial inhibitory G-proteins in catecholamine-refractory septic shock or in septic multiorgan failure.

M Böhm1, R Kirchmayr, P Gierschik, E Erdmann.   

Abstract

PURPOSE: The aim of the study was to investigate the mechanisms of myocardial catecholamine refractoriness in septic shock.
METHODS: The inhibitory guanine nucleotide-binding proteins (Gi alpha) were studied with pertussis toxin labeling and radioimmunologically in myocardium from patients who died while in catecholamine-refractory septic shock and from patients who died of noncardiac disease.
RESULTS: An increase by 62% (immunological Gi alpha) and 221% (pertussis toxin substrate) of myocardial Gi alpha was observed in patients with catecholamine-refractory shock compared with controls. The increases of Gi alpha were greater than those found in chronic heart failure reported earlier.
CONCLUSIONS: An increase in the expression of Gi alpha could also be important in conditions other than chronic heart failure, eg, septic shock. An increase of Gi alpha could play a pathophysiologically relevant role in catecholamine refractoriness in septic shock and could provide a target for pharmacologic treatment in this condition.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7847435     DOI: 10.1016/S0002-9343(99)80402-1

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  16 in total

Review 1.  The apelinergic system: a perspective on challenges and opportunities in cardiovascular and metabolic disorders.

Authors:  Eric Marsault; Catherine Llorens-Cortes; Xavier Iturrioz; Hyung J Chun; Olivier Lesur; Gavin Y Oudit; Mannix Auger-Messier
Journal:  Ann N Y Acad Sci       Date:  2019-06-25       Impact factor: 5.691

Review 2.  Use of inotropes and vasopressor agents in critically ill patients.

Authors:  Mansoor N Bangash; Ming-Li Kong; Rupert M Pearse
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

3.  Combining an antiviral with rituximab in EBV-related haemophagocytic lymphohistiocytosis led to rapid viral clearance; and a comprehensive review.

Authors:  Christos Stefanou; Christiana Tzortzi; Fotini Georgiou; Chrystalla Timiliotou
Journal:  BMJ Case Rep       Date:  2016-12-09

Review 4.  Pathophysiology of sepsis-related cardiac dysfunction: driven by inflammation, energy mismanagement, or both?

Authors:  Konstantinos Drosatos; Anastasios Lymperopoulos; Peter Johannes Kennel; Nina Pollak; P Christian Schulze; Ira J Goldberg
Journal:  Curr Heart Fail Rep       Date:  2015-04

Review 5.  Role of G-proteins in altered beta-adrenergic responsiveness in the failing and hypertrophied myocardium.

Authors:  M Böhm; M Flesch; P Schnabel
Journal:  Basic Res Cardiol       Date:  1996       Impact factor: 17.165

6.  Interleukin-1beta mediates endotoxin- and tumor necrosis factor alpha-induced RGS16 protein expression in cultured cardiac myocytes.

Authors:  Monica Patten; Sabine Stübe; Bryan Thoma; Thomas Wieland
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-10-18       Impact factor: 3.000

Review 7.  [Heart in sepsis : Molecular mechanisms, diagnosis and therapy of septic cardiomyopathy].

Authors:  L Martin; M Derwall; C Thiemermann; T Schürholz
Journal:  Anaesthesist       Date:  2017-07       Impact factor: 1.041

Review 8.  Molecular events in the cardiomyopathy of sepsis.

Authors:  Michael A Flierl; Daniel Rittirsch; Markus S Huber-Lang; J Vidya Sarma; Peter A Ward
Journal:  Mol Med       Date:  2008 May-Jun       Impact factor: 6.354

Review 9.  Sepsis-induced cardiomyopathy.

Authors:  Francisco J Romero-Bermejo; Manuel Ruiz-Bailen; Julian Gil-Cebrian; Maria J Huertos-Ranchal
Journal:  Curr Cardiol Rev       Date:  2011-08

10.  Phosphodiesterase 4 inhibition but not beta-adrenergic stimulation suppresses tumor necrosis factor-alpha release in peripheral blood mononuclear cells in septic shock.

Authors:  Andreas Link; Simina Selejan; Christoph Maack; Monika Lenz; Michael Böhm
Journal:  Crit Care       Date:  2008-12-17       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.